In summary, this study applied an integrated proteomics and metabolomics strategy to explore the mechanisms underlying aromatase inhibitor-related musculoskeletal syndrome (AIMSS) in patients with early breast cancer. The gene discussed is CYP19A1; the disease is breast cancer.